Latest Industry News & Trends

Market Scope provides comprehensive coverage of the ophthalmic and orthopedic markets. Our news stories are a combination of public and proprietary content ranging from coverage of international meetings, surgeon survey results and trends, analysis of company financial reports and public medical registries, press releases, and interviews with companies executive. Register today to receive free weekly email updates, our top data chart, surgeon poll results, and much more. Locked content can be accessed through a subscription to our ophthalmic or orthopedic industry newsletters.

Recently Added

9/18/2020
AcquisitionsBreakingDealsOphthalmic
Santen Acquires Eyevance Pharmaceuticals

Japan’s Santen Pharmaceutical announced Sept. 16 that it had acquired Eyevance Pharmaceuticals for $225 million in cash. In the deal, Santen Holdings US, a wholly owned subsidiary of Santen, will a...

9/18/2020
BreakingClinical TrialOphthalmicPharma
Aura Doses First Patient in Phase II Study of Suprachoroidal Administration of AU-011 for Choroidal Melanoma

Aura Biosciences announced Sept. 11 that the first patient had been dosed in a Phase II study of suprachoroidal administration of AU-011, the company’s lead product candidate, as a potential first-...

9/18/2020
BreakingGene TherapyOphthalmicRegulationRetina
GenSight Submits Lumevoq for LHON to EU for Marketing Authorization

French company GenSight Biologics announced Sept. 15 that it had submitted the marketing authorization application (MAA) for its gene therapy Lumevoq to the European Medicines Agency (EMA), seeking...

9/18/2020
BreakingDeviceOphthalmic
Azalea Vision of Belgium to Develop Smart Contact Lens with Dynamic Artificial Iris

Azalea Vision, a Belgium spinout, will develop a smart contact lens designed to function as an artificial iris, according to four research groups that collaborated on the prototype. The groups are ...

9/18/2020
BreakingDiagnosticOphthalmicRetina
Visible Genomics Launches DNA Testing for AMD Risk

Visible Genomics, a Chicago-area genetics testing company, announced Sept. 14 that it had launched a non-invasive genetic eye test that determines a patient’s likelihood of contracting age-related ...

9/18/2020
BreakingGlaucomaOphthalmicPharmaRegulation
US FDA Clears Aerie’s Ireland Facility for Production of Rhopressa

Aerie Pharmaceuticals announced Sept. 15 that its sterile fill production facility in Athlone, Ireland, had received approval from the US FDA for production of glaucoma drug Rhopressa (netarsudil o...

9/18/2020
BreakingClinical TrialDiagnosticOphthalmicRetina
LumiThera, Diopsys Team Up for Study of Photobiomodulation in Dry AMD

LumiThera, of Seattle, announced Sept. 10 that it is collaborating with Diopsys to support the ELECTROLIGHT study in dry age-related macular degeneration (AMD). The study will be conducted at the P...

9/15/2020
DiagnosticOCTOphthalmicPress Release
Innovations Will Propel OCT Market to $549 Million in Revenue in 2020

Recent innovations in optical coherence tomography (OCT) technology—such as systems that are combined with fundus imagers—and software advancements, including OCT angiography, are growing in popula...

9/11/2020
BreakingCataractDealsLaserOphthalmic
PDL BioPharma to Spin off LENSAR on Oct. 1

PDL BioPharma announced Sept. 10 that it would spin off its LENSAR subsidiary on Oct. 1. LENSAR, which sells the LENSAR Laser System for femtosecond-laser assisted cataract surgery (FLACS), has bee...

9/11/2020
BreakingOphthalmicPharmaRegulationRetina
France Imposes $527 Million in Fines on Novartis, Roche, Genentech Over Claims Related to Lucentis Tactics

French antitrust authorities announced Sept. 9 that they have imposed fines totaling $527 million (€445 million) on Swiss companies Novartis and Roche, plus Roche subsidiary Genentech, claiming tha...

9/11/2020
BreakingOphthalmicRetinaStudy
Study Finds that Boosting NAD+ Levels Can Prevent Retinal Disease

A preclinical study at Emory University has found that a vitamin B3 derivative called nicotinamide riboside prevents light-induced retinal damage in mice. The study, led by ophthalmology professorJ...

9/11/2020
BreakingCataractOphthalmicRegulationSurgical
Ocular Therapeutix Reports Resolution of FDA Warning Letter from 2018

Ocular Therapeutix reported Sept. 9 that is had closed out a warning letter from the US FDA related to ReSure Sealant. The Bedford, Massachusetts, company launched ReSure Sealant in the US in 2014 ...

Past News Stories

9/11/2020
BreakingOphthalmicRefractiveSurgical
BVI Introduces Malosa Refractive Single-Use Instruments to US

BVI has expanded its Malosa range of single-use ophthalmic instruments in the US to include specialty instruments for use in corneal refractive procedures such as LASIK, PRK, and SMILE, the company...

9/11/2020
BreakingOphthalmicRegulationSurgical
AMA Issues CPT Category III Codes for Artificial Iris Implantation

The American Medical Association has issued three separate CPT codes for the insertion of an iris prosthesis, according to a news release Sept. 8 from VEO Ophthalmics, of Cincinnati. The CPT Catego...

9/11/2020
BreakingOphthalmicPharmaRegulationRetina
Scotland OKs Reimbursement for Alimera’s Iluvien for Non-Infectious Posterior Uveitis 

Alimera Sciences announced Sept. 8 that the Scottish Medicines Consortium, after completing its assessment and review, had accepted Iluvien (fluocinolone acetonide intravitreal implant) 0.19 mg for...

9/11/2020
BreakingClinical TrialOphthalmicRetinaSurgical
American BriVision Says Phase I Results Support Advancement of Vitargus

American BriVision reported on Sept. 9 results from its Phase I clinical trial of its vitreous substitute product candidate Vitargus. The Fremont, California, company said the safety and preliminar...

9/11/2020
BreakingCataractClinical TrialOphthalmicSurgical
Ocular Therapeutix Doses First Patients in Phase III trial of Dextenza in Children

Ocular Therapeutix, of Bedford, Massachusetts, announced Sept. 10 that it had dosed the first patients in a Phase III trial of Dextenza (dexamethasone ophthalmic insert) 0.4 mg for ocular inflammat...

9/11/2020
BreakingClinical TrialOphthalmicPharmaRetina
Gemini Enrolls First Patient in Phase IIa Study of Dry AMD Candidate

Gemini Therapeutics announced Sept. 10 that it had enrolled the first patient in its Phase IIa study of GEM103, a recombinant Complement Factor H for geographic atrophy (GA) secondary to dry age-re...

9/11/2020
BreakingFundingOphthalmicRetina
Lineage Wins Israeli Grant to Partner on Development of Bio-Retinal Patch

Lineage Cell Therapeutics announced Sept. 8 that it had been awarded a research and development grant of up to 1.95 million Israeli New Shekels (approximately $573 thousand) from the Israel Innovat...

9/11/2020
BreakingFundingOphthalmicPharmaRefractive
Orasis Raises $30 Million to Advance Eye Drop for Presbyopia into Phase III

Israel’s Orasis Pharmaceuticals announced Sept. 10 that it had closed a $30 million Series C financing. The financing was led by new investor Bluestem Capital and returning investor Visionary Ventu...

9/4/2020
BreakingClinical TrialCornealOphthalmic
Surgeons Rebuild Corneas Using Stem Cells from Patients

Surgeons at Massachusetts Eye and Ear have rebuilt damaged corneas in four patients using the patients’ own stem cells in a first-of-its-kind procedure in the US, the Harvard teaching hospital anno...

9/4/2020
BreakingDiagnosticOphthalmicRefractive
Topcon Launches its Aladdin-M in US  

Topcon announced Aug. 28 that it had launched its new Aladdin-M instrument in the US market. The company said the device supports myopia management by combining corneal topography, pupillometry, an...

9/4/2020
BreakingCataractIOLOphthalmicSurgical
J&J Launches TECNIS Synergy, Eyhance IOLs in Canada

Johnson & Johnson Vision announced Aug. 13 that it had launched the TECNIS Synergy and TECNIS Eyhance intraocular lenses (IOLs) in Canada. The Santa Ana, California-based J&J unit said the TECNIS S...

9/4/2020
BreakingDiagnosticGlaucomaOphthalmicRegulation
Injectsense Implantable IOP Monitor Gets US FDA Breakthrough Device Nod

Injectsense, of Emeryville, California, announced Sept. 1 that it had received the US FDA breakthrough device designation for its continuous intraocular pressure (IOP) monitoring system for glaucom...

Want to Read the Full Article?

Register A Corporate Account

A corporate accounts gives you access to licensed reports and subscriptions, the latest news, and a personalized dashboard.

Select one or more
Select one or more

Market Scope

13421 Manchester Road, Suite 201 | St. Louis, MO 63131 | Phone: 314-835-0600 | Email: info@market-scope.com

©2020 Market Scope, LLC. All Rights reserved.